Decoy Therapeutics Reports Q2 Loss, Going Concern Warning, and Nasdaq Delisting Risk
DCOY is trading near its 52-week low of $3.51 (2.6% above the low) on light trading volume (0.1× avg).
Summary
Decoy Therapeutics reported a $4.6 million net loss for H1 2026, warned of going concern doubts, and disclosed a new Nasdaq delisting risk. The stock trades near its 52-week low.
Key Events · Earnings and Guidance · DCOY
-
Going Concern Warning
The company states there is substantial doubt about its ability to continue as a going concern, with cash of $8.3 million as of June 30, 2026, expected to fund operations only into late 2026.
-
Nasdaq Delisting Risk
A new risk factor discloses that if the SEC approves Nasdaq's proposed $5 million market value standard, Decoy's common stock could be imminently delisted because its market value is below the threshold.
-
H1 2026 Net Loss
Net loss for the six months ended June 30, 2026 was $4.6 million, compared to $2.7 million in the prior year period, driven by increased R&D spending on the IMP3ACT platform.
-
Private Placement Details
The 10-Q confirms the June 29, 2026 private placement raised $3.5 million upfront at $5.91 per share, with milestone warrants potentially adding up to $17.5 million more if exercised.
Analysis · DCOY · Life Sciences
Decoy Therapeutics' 10-Q reveals a $4.6 million net loss for the first half of 2026, cash of $8.3 million, and a going concern warning stating substantial doubt about its ability to continue operations. The company also disclosed a new risk factor regarding Nasdaq's proposed $5 million market value standard, which could lead to imminent delisting if approved. The stock trades near its 52-week low at $3.60, and the company's market cap is only about $2.1 million, making the delisting risk acute.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DCOY was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $3.51 to $106.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.